Approval of Dupixent: The European Commission has approved Dupixent (dupilumab) as a first-line treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 and older who do not respond adequately to H1 antihistamines and are naïve to anti-IgE therapy.
Global Availability: Dupixent is also approved for chronic spontaneous urticaria in certain adults and adolescents in multiple countries, including the US and Japan.
Understanding CSU: Chronic spontaneous urticaria is an inflammatory skin disease characterized by sudden hives and itching, often inadequately managed by standard H1 antihistamines, leaving many patients with limited treatment options.
Impact on Quality of Life: The symptoms of CSU can be debilitating and significantly affect the quality of life for those who do not respond to conventional treatments.
Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 808.50 USD with a low forecast of 637.00 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 808.50 USD with a low forecast of 637.00 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 755.510
Low
637.00
Averages
808.50
High
1057
Current: 755.510
Low
637.00
Averages
808.50
High
1057
Evercore ISI
Outperform
maintain
$750 -> $875
2026-01-22
New
Reason
Evercore ISI
Price Target
$750 -> $875
AI Analysis
2026-01-22
New
maintain
Outperform
Reason
Evercore ISI raised the firm's price target on Regeneron to $875 from $750 and keeps an Outperform rating on the shares. Regeneron is "looking strong with a refreshed outlook" and recent price hikes, argues the analyst. The company's growth prospects are "particularly buoyed" by Dupixent and Eylea HD, which are positioned well to compete in the market, the analyst tells investors.
Goldman Sachs
Buy
maintain
$807 -> $914
2026-01-08
Reason
Goldman Sachs
Price Target
$807 -> $914
2026-01-08
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Regeneron to $914 from $807 and keeps a Buy rating on the shares. After strong sector performance in 2025 driven by market dynamics, easing policy risks, and improving fundamentals, momentum is expected to continue in 2026 as these factors and their secondary effects, such as M&A, persist, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REGN
Unlock Now
BofA
Underperform
to
Buy
upgrade
$627 -> $860
2026-01-07
Reason
BofA
Price Target
$627 -> $860
2026-01-07
upgrade
Underperform
to
Buy
Reason
BofA upgraded Regeneron to Buy from Underperform with a price target of $860, up from $627.
BofA
Underperform
to
Buy
upgrade
$627 -> $860
2026-01-07
Reason
BofA
Price Target
$627 -> $860
2026-01-07
upgrade
Underperform
to
Buy
Reason
As previously reported, BofA double upgraded Regeneron to Buy from Underperform with a price target of $860, up from $627. The firm's more bullish view is driven by multiple factors, including the fact that its prior Underperform thesis around Eylea SD has played out as consensus estimates have come down. In addition, the firm is more bullish on Eylea HD's potential in light of multiple label updates and its estimates are now "meaningfully higher" than consensus, the analyst tells investors. The firm also sees potential for further upside from Dupixent and potential upside from the pipeline in 2026.
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
